Amendments to the Specification:

A. Please replace paragraph 241 with the following amended paragraph:

[0001] More particularly, the present invention relates to the use of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3- carboxamide, its pharmaceutically acceptable salts and their solvates for the preparation of drugs useful in the treatment of appetency disorders. This particularly preferred cannabinoid antagonist is ~~SR 141616 and is~~ of the formula:



B. Please replace paragraph 242 with the following amended paragraph:

[0002] Another group of exemplary cannabinoid CB1 receptor antagonists for use according to the invention are pyrazole derivatives according to Formula (I) of U.S. Patent No. 6,028,084 which is incorporated by reference in its entirety. These antagonists are of the general formula:



wherein R_1 is a fluorine, a hydroxyl, a (C_1-C_5)alkoxy, a (C_1-C_5)alkylthio, a hydroxy(C_1-C_5)alkoxy, a group -$NR_{10}R_{11}$, a cyano, a (C_1-C_5)alkylsulfonyl or a (C_1-C_5)alkylsulfinyl;

R_2 and R_3 are a (C_1-C_4)alkyl or, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated 5- to 10-membered heterocyclic radical which is unsubstituted or monosubstituted or polysubstituted by a (C_1-C_3)alkyl or by a (C_1-C_3)alkoxy;

R_4, R_5, R_6, R_7, R_8 and R_9 are each independently hydrogen, a halogen or a trifluoromethyl, and if R_1 is a fluorine, R_4, R_5, R_6, R_7, R_8 and/or R_9 can also be a fluoromethyl, with the proviso that at least one of the substituents R_4 or R_7 is other than hydrogen; and

R_{10} and R_{11} are each independently hydrogen or a (C_1-C_5)alkyl, or R_{10} and R_{11}, together with the nitrogen atom to which they are bonded, form a heterocyclic radical selected from pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl and piperazin-1-yl, which is unsubstituted or substituted by a (C_1-C_4)alkyl,

and their salts and their solvates.